The HighLife deal is seen by Sorin as a complement to its investment in Cardiosolutions, which is developing an innovative percutaneous mitral repair system.?
Sorin Group, an Italy-based cardiac device maker, has invested €4.2m ($6m) in HighLife, an early-stage company focused on the development of a transcatheter mitral valve replacement system, with an option to buy the France-based start-up.
The HighLife deal is seen by Sorin as a complement to its investment in Cardiosolutions, which is developing an innovative percutaneous mitral repair system.
André-Michel Ballester, chief executive of Sorin, said: “The HighLife investment is an important step forward in our long-term plan to build…
